Associated Genetic Biomarkers
PRKACA is altered in 1.56% of all cancers with fibrolamellar carcinoma and hepatocellular carcinoma having the greatest prevalence of alterations .
PRKACA status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains PRKACA status as an inclusion criterion, 1 is phase 1 (1 open).
The most frequent alteration to serve as an inclusion eligibility criterion is DNAJB1-PRKACA Fusion .
Significance of PRKACA in Diseases
Fibrolamellar Carcinoma +
PRKACA is altered in 900.0% of fibrolamellar carcinoma patients .
PRKACA is an inclusion criterion in 1 clinical trial for fibrolamellar carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PRKACA status and fibrolamellar carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.